Case 1:16-cv-00275-SLR-SRF Document 109 Filed 03/01/17 Page 1 of 10 PageID #: 3036
`
`IN THE UNITED STATES DISTRICT COURT
`FOR THE DISTRICT OF DELAWARE
`
`BOSTON SCIENTIFIC CORP. and
`BOSTON SCIENTIFIC SCIMED, INC.,
`
`Plaintiffs,
`
`v.
`
`EDWARDS LIFESCIENCES CORP.,
`
`Defendant.
`
`EDWARDS LIFESCIENCES CORP.,
`EDWARDS LIFESCIENCES PVT, INC., and
`EDWARDS LIFESCIENCES LLC,
`
`Counterclaim and Third-Party
`Plaintiffs,
`
`v.
`
`BOSTON SCIENTIFIC CORPORATION,
`BOSTON SCIENTIFIC SCIMED, INC., and
`SADRA MEDICAL, INC.,
`
`Counterclaim and Third-Party
`Defendants.
`
`C.A. No. 16-275-SLR-SRF
`
`DECLARATION OF PROFESSOR STEPHEN J.D. BRECKER IN SUPPORT OF
`BOSTON SCIENTIFIC’S REPLY CLAIM CONSTRUCTION BRIEF
`
`I, Stephen J.D. Brecker, state and declare as follows:
`
`1.
`
`2.
`
`I am over the age of 21 and am competent to make this declaration.
`
`I am an interventional cardiologist with a special interest in adult structural heart
`
`disease and valvular intervention. I have over 25 years of medical experience as a practicing
`
`interventional cardiologist. I am the Chief of Cardiology at St. George’s University Hospitals in
`
`Page 1
`
`Edwards Lifesciences Corporation, et al., Exhibit 1067, p. 1 of 59
`
`

`

`Case 1:16-cv-00275-SLR-SRF Document 109 Filed 03/01/17 Page 2 of 10 PageID #: 3037
`
`London, U.K. I have performed over one thousand transcatheter aortic valve replacement
`
`(“TAVR”) procedures.
`
`3.
`
`I graduated from St. Thomas’ Hospital, London, in 1984. Subsequently, I
`
`completed senior house officer posts at the Hammersmith Hospital, the Brompton Hospital, and
`
`the National Hospital for Nervous Diseases. I then completed registrar training in cardiology at
`
`St. Thomas’ Hospital and the London Chest Hospital, before taking up a British Heart
`
`Foundation Junior Research Fellowship at the Royal Brompton Hospital. I was also a visiting
`
`fellow at Johns Hopkins Hospital, Baltimore, before becoming a Consultant Cardiologist and
`
`Honorary Senior Lecturer at St. George’s in 1996. I am now Professor of Cardiology and Chief
`
`of Cardiology Clinical Academic Group at St. George’s University Hospitals.
`
`4.
`
`5.
`
`My full qualifications are set forth in my CV, attached hereto at Exhibit A.
`
`I have proctored over 600 TAVR procedures in which I assist and teach other
`
`physicians how to perform TAVR. I have been and remain a Global proctor for Medtronic since
`
`2010 at approximately 80 centers worldwide, including over 50 medical centers in the USA for
`
`the US Pivotal Trial of the Corevalve product. I have also proctored the TAVR procedure in the
`
`UK, Denmark, Belgium, Japan, India, Israel, Holland, Austria, Greece, and South Korea.
`
`6.
`
`I have performed TAVR procedures with Medtronic’s Corevalve and Evolut R
`
`products, as well as Boston Scientific’s Lotus product and Edwards’s Sapien products.
`
`7.
`
`I have been active in the field of TAVR as a clinician, researcher, teacher, and
`
`innovator, and I have performed over 1,000 percutaneous TAVR procedures since 2007.
`
`8.
`
`I have been a practicing cardiologist since 1996 and I am aware of the
`
`technological advances since then.
`
`Page 2
`
`Edwards Lifesciences Corporation, et al., Exhibit 1067, p. 2 of 59
`
`

`

`Case 1:16-cv-00275-SLR-SRF Document 109 Filed 03/01/17 Page 3 of 10 PageID #: 3038
`
`9.
`
`I am a named inventor on one patent, describing a specific TAVR guidewire,
`
`acquired by Medtronic, and two patent applications, one for a transcatheter mitral valve, and one
`
`for a novel temporary pacing wire.
`
`10.
`
`I am a Fellow of the Royal College of Physicians, the European Society of
`
`Cardiology, the American College of Cardiology, the British Cardiovascular Society, and the
`
`British Cardiovascular Intervention Society.
`
`11.
`
`I am the author or co-author of four books, 16 book chapters, and more than 100
`
`peer-reviewed articles.
`
`12.
`
`For my time, I am being compensated at $800 per hour, my standard rate for this
`
`type of consulting activity. My compensation is in no way contingent on the results of these or
`
`any other legal proceedings.
`
`Opinions Regarding Dr. Buller’s Declaration And The ‘608 Patent
`
`13.
`
`I have reviewed U.S. Patent No. 8,992,608 (the “‘608 patent”), the parties’ claim
`
`construction briefs, and Dr. Buller’s declaration regarding the ‘608 patent. I provide the
`
`following opinions regarding these materials.
`
`14.
`
`In Paragraph 27 of Dr. Buller’s declaration, he sets out his instructions regarding
`
`the interpretation of claim terms in a patent. (Buller ¶ 27.) I have followed these same
`
`instructions in coming to my opinions in this Declaration.
`
`15.
`
`In Paragraph 28 of Dr. Buller’s declaration, he sets out his instructions regarding
`
`the standard of evaluating whether a patent claim is indefinite. (Buller ¶ 28.) I have followed
`
`these same instructions in coming to my opinions in this Declaration.
`
`16.
`
`In Paragraph 31 of Dr. Buller’s declaration, he opines that a person of ordinary
`
`skill in the art would have been an “interventional cardiologist with a working knowledge of
`
`Page 3
`
`Edwards Lifesciences Corporation, et al., Exhibit 1067, p. 3 of 59
`
`

`

`Case 1:16-cv-00275-SLR-SRF Document 109 Filed 03/01/17 Page 4 of 10 PageID #: 3039
`
`heart valve designs and endovascular prostheses, including expandable stents, stent-grafts, and
`
`transcatheter heart valves, including transcatheter aortic heart valves. This person of ordinary
`
`skill in the art would, where necessary, work as a team in combination with a medical device
`
`engineer to fabricate a THV device.” (Buller ¶ 31.) I agree generally with this definition,
`
`however, it is my opinion that a person of ordinary skill in the art could also include a cardiac
`
`surgeon with experience implanting aortic valve prosthesis in the heart.
`
`17.
`
`Dr. Buller asserts that “wrinkling or pleating can involve several variables. In my
`
`opinion, three of those variables are particularly important for purposes of determining whether
`
`the phrases ‘flaps’ and ‘pockets’ as used in the ’608 patent inform, with reasonable certainty,
`
`those skilled in the art about the scope of the invention: magnitude, orientation, and
`
`formation.” (Buller ¶ 49.) I disagree that any of these “variables” need to be known in advance
`
`or quantified in order to determine whether a device has “flaps” or “pockets” within the meaning
`
`of the claims of the ‘608 patent. The word “flaps” in the claim and in the context of the
`
`description in the specification is clear and means fabric that projects from the anchor. To
`
`determine whether a device has “flaps” or “pockets,” it is not necessary to determine whether the
`
`fabric projects a little or a lot, whether it is oriented in a certain direction, or how the fabric flap
`
`is formed. Instead, the fabric simply needs to project from the anchor in order to form flaps.
`
`Of course, the claim also requires the fabric flaps to (i) be part of a fabric seal and (ii) extend into
`
`the gaps formed by the native valve leaflets.
`
`18.
`
`Dr. Buller describes several pieces of prior art that show what he considers to be
`
`flaps and pockets. The stent graft shown in paragraph 45 of Dr. Buller’s declaration (the EVT
`
`endograft) does not appear to have flaps or pockets that project away from the anchor.
`
`(Buller ¶ 45.) To be sure, there are wrinkles shown in the left-most diagram of paragraph 45, but
`
`Page 4
`
`Edwards Lifesciences Corporation, et al., Exhibit 1067, p. 4 of 59
`
`

`

`Case 1:16-cv-00275-SLR-SRF Document 109 Filed 03/01/17 Page 5 of 10 PageID #: 3040
`
`it is not clear whether the wrinkles extend inwardly into the holes between the anchor’s struts or
`
`whether they project away from the anchor. Regardless, persons of ordinary skill in the art
`
`would not have considered the covering around an endograft like the EVT endograft to have
`
`been suitable as a fabric seal in highly diseased and calcified locations, such as in a diseased
`
`aortic annulus. The covering around the EVT endograft shown in Dr. Buller’s declaration does
`
`not form flaps and pockets that would extend into the gaps form by native aortic valve leaflets.
`
`19.
`
`Dr. Buller points to several other pieces of prior art that he contends show “flaps
`
`and pockets” (Buller ¶¶ 46-48), but I do not believe this is relevant to the question of whether the
`
`terms “flaps” and “pockets” in the ‘608 patent are indefinite. I have not yet considered whether
`
`the prior art shows “flaps” and “pockets.”
`
`20.
`
`Dr. Buller provides three specific bases for his opinion that the term “flaps” is
`
`indefinite: he asserts that a person of ordinary skill in the art would not know the magnitude,
`
`orientation, and formation of the claimed “flaps.” (Buller ¶ 49.) I disagree.
`
`21.
`
`First, Dr. Buller asserts that “[a]ny fabric covering with wrinkles, for example,
`
`could be said to have portions that project from the anchor slightly along the wrinkles. Even
`
`very smooth fabric seals could project from the anchor at least in those areas along the open cells
`
`of the anchor due to the crimping process and the subsequent expansion of the valve, much like
`
`the wrinkles that form in clothing. The person of ordinary skill is thus left to guess whether any
`
`not-smooth portions of the fabric constitute ‘flaps.’” (Buller ¶ 50.) I disagree with Dr. Buller’s
`
`suggestion that a flap must project from the anchor by a predetermined distance in order to be a
`
`flap. The claims of the ‘608 patent require that the flaps be part of a “fabric seal,” and, therefore,
`
`they are designed to “seal” the spaces between the anchor and the native aortic annulus.
`
`Additionally, the claims require that the flaps extend into the gaps formed by the native valve
`
`Page 5
`
`Edwards Lifesciences Corporation, et al., Exhibit 1067, p. 5 of 59
`
`

`

`Case 1:16-cv-00275-SLR-SRF Document 109 Filed 03/01/17 Page 6 of 10 PageID #: 3041
`
`leaflets. Persons of ordinary skill in the art at the relevant time would have known generally that
`
`such gaps are on the order of millimeters and, therefore, they would expect the flaps to be on that
`
`order of magnitude in size as a general matter. However, these gaps vary from patient to patient
`
`and there could be a patient in which the gaps were very small and only a “wrinkle” in the fabric
`
`would suffice to extend into the gap.
`
`22.
`
`Thus, Dr. Buller’s assertion that “[a]ny fabric covering with wrinkles” might form
`
`flaps could be true as a structural matter if the fabric has portions that project away from the
`
`anchor. (Buller ¶ 50.) However, in order to satisfy the rest of the claim, these “wrinkles” would
`
`also have to extend into the gaps formed by the native valve leaflets. This surrounding claim
`
`language combined with the knowledge of a person of ordinary skill, who would know generally
`
`the size of the gaps that need to be sealed by the flaps (generally millimeters), provides an
`
`objective guide for determining whether the fabric projecting from the anchor would form
`
`“flaps” that meet the other requirements of the claims of the ‘608 patent.
`
`23.
`
`I disagree with Dr. Buller’s opinion that the ’608 patent provides “no guidance
`
`regarding when a fabric covering that is not completely smooth can be said to comprise ‘flaps.’”
`
`(Buller ¶ 50.) I do not see any requirement in the claims or the specification of the ‘608 patent
`
`that the flaps must project away from the anchor by a certain, required distance that is known in
`
`advance. Yet, Dr. Buller appears to assume this as a premise and then formulate his opinion
`
`based on that premise. In order to form flaps, a fabric seal that is not completely smooth must
`
`have portions that project away from the anchor—this is a clear definition that a person of
`
`ordinary skill could readily apply to determine whether a device satisfies this claim element.
`
`24.
`
`Regardless, however, the magnitude of the “flaps” in the claimed invention would
`
`generally be known by persons of ordinary skill. The specification and surrounding claim
`
`Page 6
`
`Edwards Lifesciences Corporation, et al., Exhibit 1067, p. 6 of 59
`
`

`

`Case 1:16-cv-00275-SLR-SRF Document 109 Filed 03/01/17 Page 7 of 10 PageID #: 3042
`
`language provides objective guidance as to the size of the flaps; they would be large enough to
`
`extend into the gaps formed by the native valve leaflets in order to form a seal. Generally, the
`
`aortic annulus is 20-25 millimeters in diameter. A person of ordinary skill in the art would know
`
`generally that the gaps between the device and the native valve leaflets would be on the order of
`
`a few millimeters. Some patients may have gaps up to 5 millimeters and some patients may have
`
`very small gaps of less than a millimeter, but generally the gaps would be around a millimeter or
`
`two and the vast majority of patients would have gaps within the range of about 0.1 millimeters
`
`to about 5 millimeters.
`
`25.
`
`Dr. Buller relatedly opines that “[e]ven very smooth fabric seals could project
`
`from the anchor at least in those areas along the open cells of the anchor due to the crimping
`
`process and the subsequent expansion of the valve, much like the wrinkles that form in clothing.
`
`The person of ordinary skill is thus left to guess whether any not-smooth portions of the fabric
`
`constitute ‘flaps.’” (Buller ¶ 50.) I disagree. While it is true that some seals could project from
`
`the anchor by only a small amount (due, for example, to the crimping process and subsequent
`
`expansion of the valve) and form wrinkles like those in clothing, these wrinkles would be
`
`considered “flaps” if they project away from the anchor. These flaps, however, would also have
`
`to extend into the gaps formed by native valve leaflets in order to satisfy the rest of the claim
`
`elements of the ‘608 patent.
`
`26.
`
`Second, Dr. Buller’s opinion that the orientation of the flaps supports
`
`indefiniteness is itself unclear. He argues that circumferentially-oriented flaps (i.e., flaps going
`
`around the device) tend to provide a seal and that longitudinally-oriented flaps (i.e., flaps running
`
`along the length of the device) tend not to provide a seal. (Buller ¶ 51.) I disagree with his
`
`assumption that longitudinally-oriented flaps would tend not to provide a seal; such a flap could
`
`Page 7
`
`Edwards Lifesciences Corporation, et al., Exhibit 1067, p. 7 of 59
`
`

`

`Case 1:16-cv-00275-SLR-SRF Document 109 Filed 03/01/17 Page 8 of 10 PageID #: 3043
`
`seal a longitudinally-oriented gap between the device and surrounding tissue. In any event, Dr.
`
`Buller’s conclusion that “[i]f ‘flaps’ as claimed can broadly include structures that promote
`
`rather than prevent leaks, the claims fail to inform, with reasonable certainty, those skilled in the
`
`art about the scope of the invention,” does not logically follow. (Buller ¶ 50.) The issue here is
`
`whether the term “flaps” is indefinite and in my opinion it is not—it is fabric that projects from
`
`the anchor. The orientation of the flaps generally takes the form of the gaps between the device
`
`and the anatomy, which varies from patient to patient. In fact, the orientation of these gaps can
`
`vary even within a single patient’s aortic annulus, which is an irregularly-shaped site of disease.
`
`The specification provides that the fabric seal “bunches up” to form flaps and pockets that extend
`
`into the gaps formed by native valve leaflets. Thus, the flaps and pockets may have any
`
`orientation, and a person of ordinary skill in the art would have well known this.
`
`27.
`
`Third, Dr. Buller appears to opine that the ‘608 patent does not specify how the
`
`flaps and pockets are formed in the seal. (Buller ¶ 54.) He asks rhetorically, “[m]ust the flaps be
`
`created as part of the transition between a smooth undeployed state and the deployed state?”
`
`(Id.) I do not see any requirements in the claim regarding how the flaps are formed. Rather, the
`
`claim simply requires that they be present when in the deployed state. A person of ordinary skill
`
`can ascertain objectively and with reasonable certainty whether a fabric seal around a device like
`
`that claimed in the ‘608 patent has flaps in the deployed state—they would ask whether the
`
`fabric projects away from the anchor. For pockets, they would look to see if the fabric seal has
`
`cavities. A person of ordinary skill would not need to know how the flaps and pockets were
`
`formed in order to determine if they are present. Thus, it seems to me irrelevant whether “the
`
`person of ordinary skill cannot use formation as a guide in order to determine whether the outer
`
`covering is within the scope of the invention,” as Dr. Buller opines. (Id.)
`
`Page 8
`
`Edwards Lifesciences Corporation, et al., Exhibit 1067, p. 8 of 59
`
`

`

`Case 1:16-cv-00275-SLR-SRF Document 109 Filed 03/01/17 Page 9 of 10 PageID #: 3044
`
`28.
`
`Dr. Buller reiterates his opinions about flaps with respect to pockets, as do I.
`
`(Buller ¶ 55.) He notes that “a person of ordinary skill in the art, would not be able to determine
`
`with reasonable certainty the boundary of what constitutes a ‘pocket’ based on the disclosures of
`
`the ’608 patent” due to the “lack of guidance regarding the magnitude of the claimed ‘pockets.’”
`
`(Id.) For the reasons stated above, I disagree. The claims do not specify a magnitude for the
`
`claimed pockets; they could be any magnitude that extends into the native valve leaflets to form
`
`a seal. And, in fact, a person of ordinary skill would generally know that this magnitude would
`
`be on the order of one to two millimeters and between 0.1 and 5 millimeters for the vast majority
`
`of patients.
`
`29.
`
`Dr. Buller’s opinion that the term “pockets” is indefinite because they could
`
`appear in many places on the device (Buller ¶ 56) is also irrelevant to the question at hand.
`
`Dr. Buller’s discussion of cavities that extend into the stent do not apply here because the claims
`
`of the ‘608 patent recite flaps and pockets that extend into the gaps formed by native valve
`
`leaflets to provide a seal. A person of ordinary skill would know objectively and with reasonable
`
`certainty whether a fabric seal formed such cavities.
`
`I declare under penalty of perjury under the laws of the United States of America that the
`
`foregoing is true and correct.
`
`Executed this 1st day of March, 2017.
`
`Stephen J.D. Brecker, MD, FACC.
`
`Page 9
`
`Edwards Lifesciences Corporation, et al., Exhibit 1067, p. 9 of 59
`
`

`

`Case 1:16-cv-00275-SLR-SRF Document 109 Filed 03/01/17 Page 10 of 10 PageID #: 3045
`
`
`CERTIFICATE OF SERVICE
`
`I, Karen L. Pascale, Esquire, hereby certify that on March 1, 2017, I caused to be
`
`electronically filed a true and correct copy of the foregoing document with the Clerk of the Court
`
`using CM/ECF (which will send notification that such filing is available for viewing and
`
`downloading to all registered counsel), and in addition caused true and correct copies of the
`
`foregoing document to be served upon the following counsel of record by e-mail:
`
`For Defendant, Edwards Lifesciences Corporation:
`
`Jack B. Blumenfeld
`Brian P. Egan
`Megan E. Dellinger
`MORRIS, NICHOLS, ARSHT & TUNNELL LLP
`1201 North Market Street
`P.O. Box 1347
`Wilmington, DE 19899-1347
`
`Nicholas P. Groombridge
`Kira A. Davis
`Catherine Nyarady
`William O’Hare
`Jenny C. Wu
`PAUL, WEISS, RIFKIND, WHARTON & GARRISON LLP
`1285 Avenue of the Americas
`New York, NY 10019-6064
`
`jblumenfeld@mnat.com
`began@mnat.com
`mdellinger@mnat.com
`
`ngroombridge@paulweiss.com
`kdavis@paulweiss.com
`cnyarady@paulweiss.com
`wohare@paulweiss.com
`jcwu@paulweiss.com
`
`
`
`
`March 1, 2017
`
`
`
`
`
`
`
`01:18654113.1
`
`
`
`
`YOUNG CONAWAY STARGATT & TAYLOR, LLP
`/s/ Karen L. Pascale
`
`Karen L. Pascale (#2903) [kpascale@ycst.com]
`Pilar G. Kraman (#5199) [pkraman@ycst.com]
`Rodney Square
`1000 North King Street
`Wilmington, DE 19801
`Telephone: (302) 571-6600
`Attorneys for Plaintiffs/Counterclaim Defendants
`Boston Scientific Corporation and Boston Scientific
`Scimed, Inc., and Third-Party Defendant Sadra
`Medical, Inc.
`
`Edwards Lifesciences Corporation, et al., Exhibit 1067, p. 10 of 59
`
`

`

`Case 1:16-cv-00275-SLR-SRF Document 109-1 Filed 03/01/17 Page 1 of 49 PageID #: 3046
`
`EXHIBIT A
`
`Edwards Lifesciences Corporation, et al., Exhibit 1067, p. 11 of 59
`
`

`

`Case 1:16-cv-00275-SLR-SRF Document 109-1 Filed 03/01/17 Page 2 of 49 PageID #: 3047
`
`
`
`
`
`
`
`
`ADDRESS :
`
`
`
`
`
`
`
`
`
`NATIONALITY :
`DATE OF BIRTH :
`
`GENERAL EDUCATION
`
`1973-1978
`
`
`
`
`
`UNDERGRADUATE EDUCATION
`
`1978-1984
`
`
`
`QUALIFICATIONS
`
`1981
`1984
`1987
`1993
`1999
`1999
`2000
`
`M.D. THESIS
`
`
`
`
`APPOINTMENTS
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`C U R R I C U L U M V I T A E
`
`STEPHEN JON DAVID BRECKER
`
`St. George’s Hospital, Blackshaw Road, London SW17 0QT
`Telephone : +44-(0)20-8725-3556
`
`Fax : +44-(0)20-8725-0211
`email : sbrecker@sgul.ac.uk
`British
`
`30th April 1960
`
`University College School, London NW3
`9 GCE 'O' Levels
`3 GCE 'A' Levels & 1 GCE 'S' Level with Distinction
`
`St. Thomas' Hospital Medical School
`University of London
`
`BSc (Hons 2,i) Pharmacology and Basic Medical Sciences
`MB, BS with Distinction
`MRCP (UK)
`MD
`FESC
`FACC
`FRCP
`
`Systolic and Diastolic Interactions in Ventricular Disease
`University of London : 1993
`
`Chief of Cardiology
`St. George's University Hospitals NHS Foundation Trust
`St. George's University of London
`
`Consultant Cardiologist,
`St. George's Hospital, London
`
`Reader in Structural Heart Disease,
`St. George's, University of London
`
`
`
`
`1
`
`Edwards Lifesciences Corporation, et al., Exhibit 1067, p. 12 of 59
`
`

`

`Case 1:16-cv-00275-SLR-SRF Document 109-1 Filed 03/01/17 Page 3 of 49 PageID #: 3048
`
`
`
`
`
`
`2005-2006 : Clinical Lead, South West London Cardiac Network
`2005-2010 : Director of Cardiac Catheterisation Laboratories
`2006-2010 : Care Group Lead - Cardiology
`Recognised Teacher of the University of London
`
`
`APPOINTMENTS
`
`
`
`
`
`
`
`
`
`
`
`
`
`HONOURS, AWARDS AND PRIZES
`
`
`
`1980
`
`1981
`
`1982
`
`1983
`
`1983
`
`1984
`
`1990
`
`1991
`
`1992
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Grainger Testimonial Prize in Pharmacology
`
`Medical Research Council BSc Scholarship
`
`Lord Riddell Surgical Prize - Proxime accessit
`
`Second Charles Box Medical Prize (Clinical Medicine)
`
`Gladstone, Stansfield, Stewart Memorial Bursary
`
`Distinction in Pathology (London Part IV MB,BS)
`
`British Heart Foundation Junior Research Fellowship
`
`E. Merck Travelling Scholarship
`
`1st Runner Up, Rhône-Poulenc Rorer / Junior Cardiac Club Travelling
`Scholarship - Investigators Awards
`
`
`2000
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`South Thames Department of Postgraduate Medical & Dental Education,
`University of London
`Certificate in Teaching
`
`2
`
`Edwards Lifesciences Corporation, et al., Exhibit 1067, p. 13 of 59
`
`

`

`Case 1:16-cv-00275-SLR-SRF Document 109-1 Filed 03/01/17 Page 4 of 49 PageID #: 3049
`
`PREVIOUS APPOINTMENTS
`
`April 1994 -
`April 1996
`
`
`
`
`April 1993 -
`April 1994
`
`
`
`
`
`
`
`
`Clinical Lecturer and Honorary Senior Registrar in Cardiology
`The London Chest Hospital, The Royal Hospitals NHS Trust,
`London.
`
`Waring Lecturer and Honorary Senior Registrar in Cardiology
`The Royal Brompton National Heart and Lung Hospital & The National
`Heart and Lung Institute, London.
`
`
`
`
`October 1990 -
`April 1993
`
`
`
`
`
`
`
`
`
`
`May 1989 -
`
`October 1990
`
`November 1988 -
`May 1989
`
`
`November 1987 -
`October 1988
`
`
`May 1987 -
`October 1987
`
`August 1986 -
`February 1987
`
`February 1986 -
`July 1986
`
`
`August 1985 -
`January 1986
`
`
`
`
`
`
`
`
`February 1985 -
`July 1985
`
`
`August 1984 -
`
`January 1985
`
`
`
`
`
`
`
`
`British Heart Foundation Junior Research Fellow,
`& Honorary Registrar in Cardiology,
`The Royal Brompton National Heart and Lung Hospital & The
`National Heart and Lung Institute, London.
`
`
`
`Registrar in Cardiology,
`The London Chest Hospital, London.
`
`Registrar in General Medicine and Cardiology,
`St. Thomas' Hospital, London.
`
`Registrar in General Medicine,
`Kingston Hospital, Surrey.
`
`Senior House Officer in Neurology,
`The National Hospital for Nervous Diseases, Queen Square, London.
`
`Senior House Officer in Cardiology,
`Brompton Hospital, London.
`
`Senior House Officer, Intensive Therapy Unit,
`St. Thomas's Hospital, London.
`
`Senior House Officer,
`Department of Renal Medicine and Immunology,
`Hammersmith Hospital and Royal Postgraduate Medical School,
`London.
`
`House Physician to The Medical Unit,
`St. Thomas's Hospital, London.
`
`House Surgeon,
`Kingston Hospital, Surrey.
`
`3
`
`Edwards Lifesciences Corporation, et al., Exhibit 1067, p. 14 of 59
`
`

`

`Case 1:16-cv-00275-SLR-SRF Document 109-1 Filed 03/01/17 Page 5 of 49 PageID #: 3050
`
`Percutaneous Guidewire
`
`US 2012/0016342 A1
`
`COURSES ORGANISED
`
`Annual Transoesophageal Echocardiography Course
`March 1995 – March 1996
`The London Chest Hospital, London
`March 1997 – March 2015
`St. George’s Hospital, London
`
`
`REVIEWER FOR JOURNALS
`
`Circulation, Journal of the American College of Cardiology, Heart, European Heart Journal, Lancet,
`Nature Clinical Practice Cardiovascular Medicine, American Journal of Cardiology,
`EuroIntervention, European Heart Journal Cardiovascualr Imaging, Clinical Cardiology,
`International Journal of Cardiology, Catheterization and Cardiovascular Interventions, Drug &
`Therapeutics Bulletin, European Journal of Cardiac Pacing and Electrophysiology, Journal of
`Cardiovascular Risk, Intensive Care Medicine and Thorax.
`
`
`SCIENTIFIC SESSION ABSRACT GRADER
`
`European Society of Cardiology, American College of Cardiology, Transcatheter Cardiovascular
`Therapeutics, British Cardiovascular Society.
`
`
`FELLOWSHIP & MEMBERSHIP OF SOCIETIES
`
`Fellow of the Royal College of Physicians
`
`Fellow of the European Society of Cardiology
`
`Fellow of the American College of Cardiology
`
`British Cardiovascular Society
`
`British Cardiovascular Intervention Society
`
`
`PATENT APPLICATIONS
`
`19.01.12
`
`25.09.13
`25.09.13
`26.09.13
`
`
`
`
`
`
`Replacement Heart Valve
`Replacement Heart Valve
`Replacement Heart Valve
`
`GB 2500432
`EP 2 641 570 A1
`US 2013/0253642 A1
`
`
`
`4
`
`Edwards Lifesciences Corporation, et al., Exhibit 1067, p. 15 of 59
`
`

`

`Case 1:16-cv-00275-SLR-SRF Document 109-1 Filed 03/01/17 Page 6 of 49 PageID #: 3051
`
`PUBLICATIONS
`
`
`Books
`
` A
`
` Timmis, S Brecker. Diagnosis in Color. Cardiology. London. Mosby-Wolfe. 1997.
`
` J Brecker, R H Anderson. The Adult Heart. London. Imperial College Press. 2000.
`
` S
`
` S
`
` J D Brecker. Percutaneous Device Closure of the Atrial Septum. Abingdon. Informa
`Healthcare. 2006.
`
` S
`
` Brecker, M Rothman. Clinical Guide to Primary Angioplasty. London. Informa Healthcare.
`2010
`
`Videotape and accompanying book
`
` S
`
` J Brecker, R H Anderson. Echo-morphologic correlates: The adult heart. London. Imperial
`College Press. 2000.
`
`
`
`
`
`5
`
`Edwards Lifesciences Corporation, et al., Exhibit 1067, p. 16 of 59
`
`

`

`Case 1:16-cv-00275-SLR-SRF Document 109-1 Filed 03/01/17 Page 7 of 49 PageID #: 3052
`
`Book Chapters
`
` S
`
` J D Brecker, P J Oldershaw. Echocardiography. In : A Martin, A J Camm (eds). Geriatric
`Cardiology. Principles and Practice. Chichester. John Wiley & Sons Ltd. 1994, 91-129.
`
` S
`
` J D Brecker. Transoesophageal echocardiography. In : A Redington, D Shore,
`P Oldershaw (eds). Congenital Heart Disease in Adults: A Practical Guide. London.
`W. B. Saunders Company Ltd. 1994, 17-27.
`
` S
`
` J D Brecker. Atrial septal defect. In : A Redington, D Shore, P Oldershaw (eds). Congenital
`Heart Disease in Adults: A Practical Guide. London. W. B. Saunders Company Ltd. 1994, 103-
`110.
`
` S
`
` J D Brecker. Ventricular septal defect. In : A Redington, D Shore, P Oldershaw (eds).
`Congenital Heart Disease in Adults: A Practical Guide. London. W. B. Saunders Company Ltd.
`1994, 111-117.
`
` J D Brecker. Atrial septal defect. In : R Pounder, M Hamilton (eds). Handbook of Current
`Diagnosis & Treatment. London. Current Medicine Inc., Churchill Livingstone. 1995, 52-53.
`
` S
`
` S
`
` J D Brecker. Eisenmenger complex. In : R Pounder, M Hamilton (eds). Handbook of Current
`Diagnosis & Treatment. London. Current Medicine Inc., Churchill Livingstone. 1995, 124-126.
`
` S
`
` J D Brecker. Heart block. In : R Pounder, M Hamilton (eds). Handbook of Current Diagnosis
`& Treatment. London. Current Medicine Inc., Churchill Livingstone. 1995, 176-178.
`
`
`S J D Brecker, M T Rothman. Implant complications and management. In : U Sigwart (ed).
`Endoluminal Stenting. London. W. B. Saunders Company Ltd. 1996, 296-305.
`
` S
`
` J D Brecker, M T Rothman. 1997. The Cordis coronary stent. In : P W Serruys (ed). Handbook
`of Coronary Stents. London. Martin Dunitz Ltd. 1997, 63-69.
`
` R
`
` Sharma, S J Brecker. Echocardiography. In : H Purcell, A Kalra (eds). Cardiology. Edinburgh.
`Elsevier Mosby Ltd. 2005, 51-57.
`
` M
`
` Hickman, S Brecker. Tips and tricks of atrial septal defect closure. In : M Sabate (ed).
`Percutaneous Cardiac Interventions. Tips and Tricks of New Techniques Beyond Stenting.
`Toulouse. PCR Publishing. 2010, 157-164.
`
`J-C Laborde, S J D Brecker. Implantation of the CoreValve aortic valve. In : J D Carroll, J G
`Webb (eds). Manual of Adult Structural Heart Disease Interventions. Philadelphia. Lippincott
`Williams & Wilkins. 2012, 267-285.
`
` W
`
` H Gaasch, S J D Brecker, G S Aldea. Transcatheter aortic valve replacement. UpToDate.
`Wolters Kluwer Health 2012-4. www.uptodate.com.
`
` P
`
` S Douglas, G S Bloomfield. S J D Brecker (Ed). Imaging for transcatheter aortic valve
`replacement. UpToDate. Wolters Kluwer Health 2014. www.uptodate.com.
`6
`
`
`
`Edwards Lifesciences Corporation, et al., Exhibit 1067, p. 17 of 59
`
`

`

`Case 1:16-cv-00275-SLR-SRF Document 109-1 Filed 03/01/17 Page 8 of 49 PageID #: 3053
`
`W H Gaasch, S J D Brecker, G S Aldea. Transcatheter aortic valve replacement: Outcomes and
`complications. UpToDate. Wolters Kluwer Health 2015. www.uptodate.com.
`
` J D Brecker, W H Gaasch, G S Aldea. Transcatheter aortic valve replacement: Indications and
`periprocedural management. UpToDate. Wolters Kluwer Health 2015. www.uptodate.com.
`
` S
`
`
`
`7
`
`Edwards Lifesciences Corporation, et al., Exhibit 1067, p. 18 of 59
`
`

`

`Case 1:16-cv-00275-SLR-SRF Document 109-1 Filed 03/01/17 Page 9 of 49 PageID #: 3054
`
`Peer Review Editorials and Reviews
`
` S
`
` J D Brecker, D G Gibson.
`Diagnosis, effects and treatment of subendocardial failure.
`Primary Cardiology 1994; 20:19-25.
`
` J
`
` N Shephard, S J Brecker, T W Evans.
`Bedside assessment of myocardial performance in the critically ill.
`Intensive Care Medicine 1994; 20:513-521.
`
` S
`
` J D Brecker.
`Myocardial infarction in patients with normal coronary arteries.
`Annals of Medicine 1994; 26:383-384.
`
` S
`
` J D Brecker.
`The leaking prosthetic valve.
`British Journal of Hospital Medicine 1996; 55:415-418.
`
` S
`
` J D Brecker, D G Gibson.
`What is the role of pacing in dilated cardiomyopathy ?
`European Heart Journal 1996; 17:819-824.
`
` S
`
` J D Brecker, D G Gibson.
`Echocardiographic evaluation of ventricular diastolic function: implications for treatment.
`Heart 1996; 76:386-387.
`
` T
`
` Treasure, S J D Brecker.
`The role of echocardiography in the diagnosis of aortic dissection.
`The Journal of Heart Valve Disease 1996; 5:623-629.
`
` S
`
` J D Brecker.
`The managememt of unstable angina.
`Drug and Therapeutics Bulletin 1998; 36:36-39.
`
` P
`
` M Elliott, S J D Brecker, W J McKenna.
`Diastolic dysfunction in hypertrophic cardiomyopathy.
`European Heart Journal 1998; 19:1125-1127.
`
` S
`
` J D Brecker.
`Pulmonary venous flow analysis after cardioversion.
`European Heart Journal 1999; 20:323-324.
`
` S
`
` J D Brecker, J R Pepper, S J Eykyn.
`Aortic root abscess.
`Heart 1999; 82:260-262.
`
`
` S
`
` J D Brecker.
`
`
`
`8
`
`Edwards Lifesciences Corporation, et al., Exhibit 1067, p. 19 of 59
`
`

`

`Case 1:16-cv-00275-SLR-SRF Document 109-1 Filed 03/01/17 Page 10 of 49 PageID #:
` 3055
`
`The importance of long axis ventricular function.
`Heart 2000; 84:577-578.
`
` R
`
` H Anderson, S Y Ho, S J Brecker.
`Anatomic basis of cross-sectional echocardiography.
`Heart 2001; 85:716-720.
`
` C
`
` Varma, S J D Brecker.
`Predictors of mortality in acute myocardial infarction.
`Lancet 2001; 358:1473-1474.
`
` D
`
` Pellerin, S J D Brecker.
`A step further in inter-institutional agreement in interpretation of dobutamine stress
`echocardiograms.
`European Heart Journal 2002; 23:768-771.
`
` N
`
` Parchure, S J D Brecker.
`Management of acute coronary syndromes.
`Current Opinion in Critical Care 2002; 8:230-235.
`
` D
`
` Pellerin, S Brecker, C Veyrat.
`Degenerative mitral valve disease with emphasis on mitral valve prolapse.
`Heart 20